Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures - Full Text View

Purpose

The study will help in identifying the best empiric antibiotic option for Linezolid resistant VRE infections. This research is important because it allows the determination of resistance rates to antibiotics that may not be frequently tested to by the clinical microbiology laboratory at UPMC-Presbyterian. It also will provide antibiotic minimum inhibitory concentrations (MICs) for these pathogens which may help in identifying the best empiric antibiotic option for Linezolid resistant VRE infections.

Condition

Isolate
Linezolid

MedlinePlus related topics:

Antibiotics

ChemIDplus related topics:

Linezolid

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective

Official Title:	Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures

Further study details as provided by University of Pittsburgh:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	20
Study Start Date:	April 2007

Detailed Description:

After 20 linezolid-resistant VRE isolates are identified, genetic relatedness will be determined using a method known as Pulse-field gel electrophoresis (PFGE). No patient related data will accompany these isolates, nor will any related identifiers. These isolates will be tested using standardized susceptibility methods. We will then grow each isolate and test via approved laboratory standards (E-test, AB Biodisk, Stockholm, Sweden) to the drug linezolid. Those determined to be resistant using this approved methodology will be saved until 20 isolates are identified. For resistant isolates found, analytical and molecular techniques will be performed to determine the mechanisms of resistance and whether resistant isolates are coming from a single source/being transmitted from person to person.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

isolates for rectal surveillance

Criteria

Inclusion Criteria:

Dr. Harrison's laboratory collected the rectal surveillance isolates for infection control purposes. The isolates will be from January 1, 2006 to December 31, 2006.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00475891

Contacts


Contact: Brian Potoski, Pharm D	412-648-6487	potoskiba@upmc.edu

Contact: Diana Lynn Pakstis, RN, BSN	412-648-6553	pakstisdl@dom.pitt.edu

Locations


United States, Pennsylvania
	University of Pittsburgh Medical Center	Recruiting
	Pittsburgh, Pennsylvania, United States, 15213
	Contact: Brian Potoski, Pharm D 412-648-6487 potoskiba@upmc.edu
	Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu
	Principal Investigator: Brian Potoski, Pharm D

Sponsors and Collaborators

University of Pittsburgh

Investigators


Principal Investigator:	Brian Potoski, Pharm D	University of Pittsburgh

More Information

Responsible Party:	UPMC ( Brian Potoski, Pharm D )
Study ID Numbers:	PRO07050007
First Received:	May 17, 2007
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00475891
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

isolate

infection

linezolid

Study placed in the following topic categories:

Linezolid

Additional relevant MeSH terms:

Protein Synthesis Inhibitors

Anti-Infective Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Enzyme Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008

Sponsored by:	University of Pittsburgh
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00475891